<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0123-9392</journal-id>
<journal-title><![CDATA[Infectio]]></journal-title>
<abbrev-journal-title><![CDATA[Infect.]]></abbrev-journal-title>
<issn>0123-9392</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Infectología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0123-93922020000500017</article-id>
<article-id pub-id-type="doi">10.22354/in.v24i3.869</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Toward to establish selection criteria for rapid serological tests for COVID-19]]></article-title>
<article-title xml:lang="es"><![CDATA[Hacia la construcción de criterios para la selección de pruebas serológicas rápidas para COVID-19]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[Johana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mercado]]></surname>
<given-names><![CDATA[Marcela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gaviria]]></surname>
<given-names><![CDATA[Paula]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Colombia Faculty of Science Department of Pharmacy]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Universitaria Sanitas  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Salud Dirección de Investigación en Salud Pública ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af4">
<institution><![CDATA[,aff4  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af5">
<institution><![CDATA[,Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud Unidad Avanzada de Inmunohematología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af6">
<institution><![CDATA[,Universidad Nacional de Colombia Faculty of Medicine Department of Internal Medicine]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>24</volume>
<numero>3</numero>
<fpage>17</fpage>
<lpage>25</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0123-93922020000500017&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0123-93922020000500017&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0123-93922020000500017&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract COVID-19, the new pandemic is associated to SARS-CoV-2 virus infection. Social distancing and the testing have been the principal measures that have shown to be effective for the reduction of critical cases. Although the gold standard for diagnosis of COVID-19 is the RT-PCR, rapid serological tests could also be used for prevalence studies, and for epidemiological monitoring. In order to characterize the humoral immune response, we analyzed eight immunochromatographic test and one ELISA test, as a verification or secondary validation analysis used positive and negative control serum samples. Sera from negative and positive individuals [asymptomatic or symptomatic individuals, outpatient or inpatientor (intensive care unit)] were analyzed, and the following results were found: of all these rapid tests, only 4 exhibit clear banding patterns for IgG and two of these also showed results for IgM (only in a few symptomatic patients). Instead, with an ELISA test a preferential recognition was observed for symptomatic patients who were critically ill, whereas in asymptomatic individuals it did not show more than 25% of positivity. Understanding and validating molecular and serological tests are an essential component for the design of public health measures to response to the pandemic.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen COVID-19 la nueva pandemia está asociada con la infección por el virus SARS-CoV-2. La distancia social y el análisis masivo de muestras son las principales medidas que se han mostrado efectivas para la reducción de los casos críticos. Aunque el estándar de oro para el diagnóstico de COVID-19 es la RT-PCR, las pruebas serológicas rápidas podrían también ser usadas en estudios de prevalencia, así como en la vigilancia epidemiológica. Con el fin de caracterizar la respuesta inmune humoral, analizamos ocho pruebas inmunocromatográficas y una prueba de ELISA, en un proceso de verificación de desempeño o validación secundaria, usando sueros control positivos y negativos. Los sueros de pacientes positivos y negativos [individuos asintomáticos o sintomáticos, pacientes ambulatorios u hospitalizados (en cuidados intensivos)] fueron analizados, encontrando los siguientes resultados: de todas las pruebas rápidas examinadas solamente 4 mostraron un claro patrón de bandas para IgG, de éstas, dos de ellas también mostraron resultados para IgM (solamente en pocos pacientes sintomáticos). En cambio, con la prueba de ELISA un reconocimiento preferencial fue observado en pacientes sintomáticos con enfermedad crítica, mientras que los individuos asintomáticos no mostraron más de un 25 % de positividad. Comprender y validar las pruebas serológicas son componentes esenciales en el diseño de las medidas de políticas públicas como respuesta a esta pandemia.]]></p></abstract>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Team]]></surname>
<given-names><![CDATA[QL]]></given-names>
</name>
</person-group>
<source><![CDATA[The 2019-nCoV Outbreak Joint Field Epidemiology Investigation. An Outbreak of NCIP (2019-nCoV) Infection in China - Wuhan, Hubei Province, 2019&#8722;2020]]></source>
<year>2020</year>
<page-range>79-80</page-range><publisher-loc><![CDATA[China ]]></publisher-loc>
<publisher-name><![CDATA[CDC Weekly]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bushman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China]]></article-title>
<source><![CDATA[Nat Med]]></source>
<year>2020</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>506-10</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>ECDC</collab>
<source><![CDATA[Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK]]></source>
<year>2020</year>
<edition>eighth update</edition>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loeffelholz]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[YW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Laboratory diagnosis of emerging human coronavirus infections - the state of the art]]></article-title>
<source><![CDATA[Emerg Microbes Infect]]></source>
<year>2020</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>747-56</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wikramaratna]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Paton]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mahan Ghafari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lourenco]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating false-negative detection rate of SARS-CoV-2 by RT-PCR]]></article-title>
<source><![CDATA[medRxiv]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wolfel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Corman]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Guggemos]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Virological assessment of hospitalized patients with COVID-2019]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Litvinova]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Birdsall]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Casadevall]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Adaptive Immunity: Antibodies and Immunodeficiencies]]></source>
<year>2014</year>
<page-range>35-50</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>WHO</collab>
<source><![CDATA[Advice on the use of point-of-care immunodiagnostic tests for COVID-19]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hilgenfeld]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peiris]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses]]></article-title>
<source><![CDATA[Antiviral Res]]></source>
<year>2013</year>
<volume>100</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>286-95</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Totura]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Baric]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon]]></article-title>
<source><![CDATA[Curr Opin Virol]]></source>
<year>2012</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>264-75</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ren]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Yi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and clinical application of a rapid IgMIgG combined antibody test for SARS-CoV-2 infection diagnosis]]></article-title>
<source><![CDATA[J Med Virol]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<collab>China MocPsro</collab>
<source><![CDATA[Heads of Related Departments of the Ministry of Commerce, the General Administration of Customs, and the National Medical Products Administration Addressing Media Questions on the Orderly Export of Medical Supplies]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<collab>ACIN</collab>
<collab>IETS</collab>
<article-title xml:lang=""><![CDATA[Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud]]></article-title>
<source><![CDATA[Infectio]]></source>
<year>2020</year>
<volume>24</volume>
<numero>^sS3</numero>
<issue>^sS3</issue>
<supplement>S3</supplement>
<page-range>1-153</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lauer]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Grantz]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Bi]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kozel]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Burnham-Marusich]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Point-of-Care Testing for Infectious Diseases: Past, Present, and Future]]></article-title>
<source><![CDATA[J Clin Microbiol]]></source>
<year>2017</year>
<volume>55</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2313-20</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zherdev]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Dzantiev]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ways to Reach Lower Detection Limits of Lateral Flow Immunoassays]]></article-title>
<source><![CDATA[Rapid Test-Advances in Design, Format and Diagnostic Applications]]></source>
<year>2018</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[IntechOpen]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Posthuma-Trumpie]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Korf]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[van Amerongen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lateral flow (immuno) assay: its strengths, weaknesses, opportunities and threats. A literature survey]]></article-title>
<source><![CDATA[Anal Bioanal Chem]]></source>
<year>2009</year>
<volume>393</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>569-82</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yongchen]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients]]></article-title>
<source><![CDATA[Emerg Microbes Infect]]></source>
<year>2020</year>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody responses to SARS-CoV-2 in patients with COVID-19]]></article-title>
<source><![CDATA[Nat Med]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rokni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ghasemi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Tavakoli]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS]]></article-title>
<source><![CDATA[Rev Med Virol]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zuo]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019]]></article-title>
<source><![CDATA[Int J Infect Dis]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Maohua]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2020</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
